Effective treatment of migraine: Terminating acute attacks, reducing their frequency

Postgraduate Medicine

Volumn 115, Issue 4, 2004, Pages 28-50

  Pringsheim, Tamara ^a   Edmeads, John ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFERGOT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; DICHLORALPHENAZONE; DIHYDROERGOTAMINE MESILATE; DIMENHYDRINATE; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; IBUPROFEN; ISOMETHEPTENE MUCATE; METHYSERGIDE MALEATE; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIZOTIFEN; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 2 ANTAGONIST; SUMATRIPTAN SUCCINATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLMITRIPTAN;

ACUTE DISEASE; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDEMA; ESOPHAGUS SPASM; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HAIR LOSS; HEADACHE; HUMAN; IMPOTENCE; LIVER DYSFUNCTION; MIGRAINE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; SIDE EFFECT; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MIGRAINE DISORDERS; PATIENT PARTICIPATION; PATIENT SELECTION; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK FACTORS; SEROTONIN AGONISTS; SUMATRIPTAN; UNITED STATES; VASOCONSTRICTOR AGENTS;

EID: 1842786898     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2004.04.1475     Document Type: Article

References (8)

1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race, and other socio-demographic factors. JAMA 1992; 267 (1): 64 – 9
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl 1): 9 – 160
3. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994; 44 (7): 1353 – 4
4. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. Can Med Assoc J 1997; 156 (9): 1273 – 87.
5. Erratum, Can Med Assoc J 1997; 157 (10): 1354
6. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55 (6): 754 – 62.
7. Erratum, Neurology 2000; 56 (1): 142
8. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358 (9294): 1668 – 75